viewLexaria Bioscience Corp.

Lexaria Bioscience wins ninth US patent as it expands patent portfolio

The new patent protects the use of Lexaria's DehydraTECH technology together with cannabinoids, nicotine and nonsteroidal anti-inflammatory drugs

Lexaria currently has 17 patents, with eight in Australia and the nine in the US, along with roughly 60 patent applications pending globally

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX), a global innovator in drug delivery platforms, has received its ninth US patent.

In a statement Tuesday, the company said the new patent provides patent claims that protect the use of its DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix-and-serve beverage formats. 

The patent is entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” -- and signifies another addition to Lexaria's first patent family.

READ: Lexaria Bioscience says it supports DehydraTECHTM licensee Boldt Runners' corporate growth initiatives

Lexaria said it has also responded to patent office queries in Europe, India, Mexico, Australia, US, Japan and Canada in recent weeks. However, the company does not expect all its applications to be successful but is optimistic of additional patent grants in some of these locations soon.

Lexaria currently has 17 granted patents, with eight in Australia and the nine in the US, along with roughly 60 patent applications pending throughout the world. 

The granted patents cover the delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. The company said patents are pending for the delivery of antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.

The Kelowna, British Columbia-based Lexaria has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Lexaria Bioscience Corp.

Price: 6.78 CAD

Market: CSE
Market Cap: $34.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...


After successful raise of 11 million dollars, Lexaria Bioscience spells out...

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives. Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension...

on 1/2/21

2 min read